A comprehensive view of Catalent Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Catalent to lay off approximately 130 staff in Bloomington, Indiana, fill-finish plant despite an upcoming takeover by Novo Holdings; the job cuts are part of an ongoing effort to consolidate and reduce costs across its operations
Published: March 22, 2024 by FiercePharma
Novo Holdings acquires contract development and manufacturing organization Catalent for US$16.5B in an all-cash deal; Novo Holdings sells three Catalent manufacturing sites to Novo Nordisk for US$11.0B to boost its diabetes and obesity supply chain
Published: February 08, 2024 by MarketLine
JPMorgan: Novo Nordisk's acquisition of production sites through Catalent is sensible move to help meet weight loss drug demand; production capacity to be increased for injectable Wegovy and Ozempic treatments, allowing Novo to ramp supply for US, world
Published: February 06, 2024 by Proactive Investors
Novo Nordisk to acquire three Catalent fill-finish sites for US$11.0B; the three sites are located in Anagni, Italy, Brussels, Belgium, and Bloomington, Indiana, and employ more than 3,000 people
Published: February 05, 2024 by GlobeNewswire Europe
Commentary: Weight-loss drugs fuel boom for firms that fill syringes used to administer treatments like Wegovy; companies like WuXi Biologics, Catalent building pre-filled syringe capacities at facilities to serve market that could top US$100B in a decade
Published: October 09, 2023 by Reuters

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count